Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep366 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Clinical pharmacology of insulin aspart: Hyperinsulinemic euglycemic clamp study of the biosimilar product

Dorotenko Artem , Makarenko Igor , Mosikyan Anna , Magruk Maksim , Drai Roman

Introduction: Rapid-acting insulins is widely used in the treatment of either type 1 diabetes mellitus, or type 2 diabetes mellitus. A mealtime injection of rapid-acting insulin, such as insulin aspart, allow the diabetic patients to control the levels of post-prandial glucose. The clinical development plan of the insulin biosimilarsusually contains pharmacology studies to evaluate pharmacokinetics (PK), pharmacodynamics (PD) and clinical safety of the investigational products...

ea0073aep233 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Efficacy and safety of gp40081 (insulin aspart biphasic 30) compared to novomix 30 flexpen in type 2 diabetes mellitus patients

Isaeva Julia , Makarenko Igor , Vinderskaya Galina , Magruk Maksim , Drai Roman

IntroductionA biosimilar is a biological medicinal product that shows high similarity to another already approved medicine product containing biotechnology-derived protein as active substance. The similarity depends on the biosimilar development program that includes comparative studies of physical and chemical properties, in vitro pharmacodynamics, pharmacokinetics and pharmacodynamics in humans. Insulin aspart biphasic 30 is one of the most co...